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uhe Relationship
etween Pre-Participation
creening of Young Competitive
thletes and Family Screening
ith great interest we read the review by Corrado et al. (1) on
re-participation screening (PPS) of young competitive athletes to
revent sudden cardiac death (SCD).
It is important that Corrado et al. (1) briefly mentioned the
ossibility of cascade screening of relatives of a competitive athlete
ith an inherited heart disease. Unfortunately, this topic is
requently neglected in articles on PPS. As the authors state,
dentifying other affected family members with subsequent high-
isk stratification and treatment can save additional lives.
Hypertrophic cardiomyopathy (HCM), which can be detected
y PPS (1), is the most important cause of SCD in young athletes.
t present, a mutation is identified in 30% to 61% of HCM
atients (2). The identification of a disease causing mutation
nables cascade screening within a family. With the developments
n diagnostic tools for DNA analysis (e.g., high-throughput
echniques), the proportion of mutations identified will probably
ncrease. In case no mutation is found (yet) in an HCM patient,
ardiological examination of first-degree relatives is the second best
ption.
One could argue that affected family members identified by
ascade screening should be taken more into account when
iscussing the efficacy of PPS. In any case, performing cascade
creening after identification of an affected athlete by PPS could
ontribute to reducing the incidence of SCD in the general
opulation.
Moreover, implementing and offering an adequate nationwide
amily screening program to relatives of young SCD victims or
atients with inherited heart disease could indentify most individ-
als and families in the country at risk of SCD. This would
otentially decrease the benefit of PPS in competitive athletes,
ecause this target group would become an even more selected
ealthy population.
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eply
e appreciate the interest of Dr. van der Werf and colleagues in
ur review (1). Their comments provide an opportunity to further
larify some aspects concerning appropriate strategies for sudden
eath prevention. The majority of conditions carrying risk of
rrhythmic cardiac arrest in young people and athletes are genet-
cally determined diseases with an autosomal dominant pattern of
nheritance. Universal evaluation of the general population for
nherited heart diseases is not currently feasible, because of the
rohibitive costs and the limited diagnostic accuracy of both
linical and genetic evaluation. A reasonable alternative strategy is
o target high-risk subgroups (1,2). Patients with cardiac symp-
oms, such as syncope or pre-syncope, are the first group that needs
ccurate cardiologic assessment. However, most inherited cardio-
yopathies (including ion channel diseases) show a silent clinical
ourse that might lead to arrhythmic cardiac arrest in the absence
f warning disabling symptoms and ventricular dysfunction (1,3).
ecause the individuals at risk are unlikely to be identified on the
asis of spontaneous symptoms, strategies for prevention of sudden
eath rely on programs of actively searching for high-risk subjects.
hese prevention strategies include: 1) pre-participation screening
f competitive athletes who show a 3-fold increase of the relative
isk of sudden cardiac death compared with their nonathletic
ounterparts; and 2) cascade screening of relatives of sudden
ardiac death victims or probands with a inherited heart disease,
ho have a 50% chance of inheriting the gene defect and the
otentially malignant clinical phenotype. The current evidence is
hat pre-participation electrocardiographic evaluation of young
ompetitive athletes is effective in identifying athletes with poten-
ially lethal cardiovascular disease and actually saves lives, although
o data on the efficacy of clinical cascade screening for sudden
eath prevention are available. At the present time, systematic
olecular genetic screening for inherited heart diseases is imprac-
ical because it is time-consuming, costly, and—particularly—lacks
ccuracy given that many disease-causing genes remain to be
iscovered. Instead, a selective genetic screening of family mem-
ers of a proband who has been identified with a causative
utation is feasible and offers clear advantages over clinical
creening. Genotyping facilitates cascade screening, because it
llows for definitive reassurance of true gene-negative family
embers and focuses prevention strategies on proven gene-
arriers. Clinical manifestations of inherited heart diseases are
sually preceded by a long “pre-clinical” phase, and cardiac arrest
ften occurs in previously asymptomatic young adults and com-
